Biotech | February 24, 2022
Aadi Bioscience launches Fyarro in the USA
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
The first wave of shipments includes several countries, such as Germany, France and Austria
Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
he financing was significantly oversubscribed with high demand from both existing and new investors.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Subscribe To Our Newsletter & Stay Updated
